McKesson (NYSE: MCK) reported Q2 EPS of $4.80, $0.93 better than the analyst estimate of $3.87. Revenue for the quarter came in at $60.8 billion versus the consensus estimate of $59.45 billion.

GUIDANCE:

McKesson sees FY2021 EPS of $16.00-$16.50, versus the consensus of $15.20.

• McKesson raised fiscal 2021 Adjusted Earnings per diluted share guidance to $16.00 to $16.50 from the previous range of $14.70 to $15.50 to reflect strong execution and earlier improvement in volumes relative to expectations through the first half of fiscal 2021. Fiscal 2021 guidance assumes approximately $0.15 to $0.20 of Adjusted Earnings per diluted share related to the kitting and storage of ancillary supplies for future COVID-19 vaccines.
• Fiscal 2021 guidance assumes that a full recovery of pharmaceutical prescription volumes and patient visits is not likely to occur this fiscal year.

For earnings history and earnings-related data on McKesson (MCK) click here.